Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with COPD

• Published in: The clinical respiratory journal Vol. 11; no. 3; pp. 318 - 327
• Main Authors: Aydin, Murat, Altintas, Nejat, Cem Mutlu, Levent, Bilir, Bulent, Oran, Mustafa, Tülübaş, Feti, Topçu, Birol, Tayfur, İsmail, Küçükyalçin, Volkan, Kaplan, Gizem, Gürel, Ahmet
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.05.2017
• Subjects: Aged; Arginine - adverse effects; Arginine - analogs & derivatives; Arginine - blood; Arginine - metabolism; asymmetric dimethylarginine–chronic obstructive pulmonary disease–nitric oxide–pulmonary function test; Biomarkers - blood; Chronic obstructive pulmonary disease; Cross-Sectional Studies; Disease Progression; Enzyme Inhibitors - adverse effects; Enzyme-Linked Immunosorbent Assay; Female; Forced Expiratory Volume - physiology; Humans; Lung - physiopathology; Male; Middle Aged; Nitric oxide; Nitric Oxide - blood; Nitric Oxide - deficiency; Prospective Studies; Pulmonary Disease, Chronic Obstructive - diagnosis; Pulmonary Disease, Chronic Obstructive - metabolism; Pulmonary Disease, Chronic Obstructive - physiopathology; Regression analysis; Respiratory Function Tests; Smoking - epidemiology; asymmetric dimethylarginine-chronic obstructive pulmonary disease-nitric oxide-pulmonary function test
• ISSN: 1752-6981; 1752-699X; 1752-699X
• DOI: 10.1111/crj.12337

Introduction Asymmetric dimethylarginine (ADMA) and nitric oxide (NO) show their mechanism of action reciprocally, the balance between these molecules contributes to the tight regulation of airways tone and function. Objectives The aim of this study to determine the serum levels of ADMA and NO in patients with chronic obstructive pulmonary disease (COPD) and establish whether their level vary in relation to forced expiratory volume in 1s (FEV1), to assess their role in pathophysiology of COPD. Materials and Methods This study consisted of 58 patients with COPD and 30 healthy subjects. Serum ADMA and NO levels were measured using enzyme‐linked immunosorbent assay and the colorimetric method, respectively. Results Serum ADMA levels were significantly higher, however, NO levels were lower in patients with COPD compared with controls. ADMA levels were inversely correlated with NO levels. Serum ADMA and NO were significantly correlated with FEV1. Multivariable logistic regression analysis revealed that serum ADMA and NO were independently and significantly associated with the presence of COPD. Multiple linear regression analysis showed that COPD was positively associated with ADMA, additionally COPD and ADMA were independently and inversely associated with NO. NO levels were decreased, ADMA levels were increased compliant with progression of COPD stages. Conclusion While circulating ADMA is higher, NO is lower in COPD and both show a strong correlation to the degree of airflow limitation. ADMA seems to be a possible new marker of prognosis of COPD and can be a novel therapeutic target for the treatment of COPD.